Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]
Allergan
Merck becomes latest to offer insight into drug pricing practices
Last week, Merck (NYSE:MRK) released figures about its U.S. pricing practices, joining a growing list of companies that are revealing their pricing strategies amid criticism of the industry’s price hikes. The company didn’t release price increases of specific products, citing competition concerns. Merck said it would update the list annually at the beginning of each calendar year. […]
Allergan pays $15m for failing to disclose Actavis ‘white knight’ offer
The SEC said yesterday that Allergan (NYSE:AGN) will pay a $15 million fine for failing to disclose its 2014 merger talks with Actavis. In June 2014, Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) offered a tender bid for the Irvine, Calif.-based company which was followed by a 7 month-long hostile pursuit by Valeant and co-bidder Pershing Square Capital Management. In November […]
J&J to publish list of average drug price increases
Johnson & Johnson (NYSE:JNJ) is reportedly issuing a report next month that will detail how much it has raised the list prices for its prescription drugs. The J&J report will describe average increases in list prices and the average prices after discounts. The move comes after some pharmaceutical companies, including Allergan (NYSE:AGN) and Novo Nordisk (NYSE:NVO), have […]
FDA accepts Allergan’s new drug application for Liletta contraception device
Allergan (NYSE:AGN) and the global nonprofit women’s health company Medicines360 said today that the FDA accepted its supplemental New Drug Application for the Liletta contraception device. The companies are asking the federal watchdog to extend the system’s duration of use from 3 years to 4 years. Liletta is a levonorgestrel-releasing intrauterine system that is placed […]
Allergan wins FDA nod for Natrelle Inspira SoftTouch breast implant
Allergan (NYSE:AGN) said today it won FDA approval for its Natrelle Inspira SoftTouch breast implants designed for breast reconstruction, augmentation or revision surgeries. The newly cleared Inspira SoftTouch implant is designed from a new medium firmness gel, the company said, bringing the total number of firmness options or its Natrelle line up to 3. “I am excited […]
Allergan picks up Acelity’s LifeCell biz for $2.9B
Acelity said today that it inked a definitive agreement with Allergan (NYSE:AGN) to sell its LifeCell business for $2.9 billion in cash. The deal will put LifeCell’s regenerative medicine and reconstructive portfolio under Allergan’s roof, joining its medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects will generate approximately $450 million in […]
Mylan, Allergan launch fight over Restasis eye drop patents
Allergan (NYSE:AGN) said this week that it will “vigorously defend” the patents for its Restasis eye drops, after the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board agreed to an inter partes review of 6 patents as requested by generic competitor Mylan (NSDQ:MYL). The patents are valid until August 2024. “Allergan is disappointed in […]
Novo Nordisk joins Allergan in pledge to limit price hikes
Novo Nordisk (NYSE:NVO) president Jakob Riis said this week that the company will limit annual price hikes of its products’ list prices to single-digit percentages, joining Allergan (NYSE:AGN) CEO Brent Saunders who released a “social contract” 3 months ago with the same goal. “We hear from more and more people living with diabetes about the challenges […]
Pharma execs assess landscape under President Trump
Executives from U.S. drugmakers such as Regeneron Pharmaceuticals (NSDQ:REGN) and Pfizer (NYSE:PFE) talked about the possible changes awaiting the industry under President-elect Donald Trump at the Forbes Healthcare Summit this week. After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants […]
Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy
Allergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio. Washington, D.C.-based Chase is developing a combination therapy of an acetylcholinesterase inhibitor and a cholinergic blocker in the hopes of improving cognition in patients with Alzheimer’s disease. The acetylcholinesterase inhibitors available on the […]